TMCnet News
BUYINS.NET: IFC, TELK, CRXX, ARBX, FACE, ZIOP Expected To Be Lower After Earnings Releases on ThursdayAug 03, 2009 (M2 PRESSWIRE via COMTEX) -- BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, August 6th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and August earnings reports. Irwin Financial (NYSE: IFC), Telik (NASDAQ: TELK0, CombinatoRx (NASDAQ: CRXX), Arbinet-thexchange (NASDAQ: ARBX), Physicians Formula Holdings (NASDAQ: FACE) and ZIOPHARM Oncology (NASDAQ: ZIOP) are all expected to be lower after their earnings are released Thursday. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php. The following stocks are expected to go lower after earnings are released Thursday: Symbol Company # of Reports Quarter Release Time IFC Irwin Financial Corp 12 quarters Q2 Before TELK Telik, Inc. 12 quarters Q2 During CRXX CombinatoRx Inc. 12 quarters Q2 Before ARBX Arbinet-thexchange Inc. 12 quarters Q2 After FACE Physicians Formula Hold 12 quarters Q2 After ZIOP ZIOPHARM Oncology, Inc. 12 quarters Q2 Before Earnings, or profits, drive stock prices. The market values a company based on its current and anticipated future ability to make money. The market takes the earnings pulse of a company four times per year when quarterly reports are issued. When this information is released it can often be a trend-changing or a trend confirming event because the information is so vital to the market's perception of the vitality of that company. This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists. Irwin Financial Corporation (NYSE: IFC) operates as the holding company for Irwin Union Bank and Trust Company and Irwin Union Bank, F.S.B., which provide various financial products and services in the United States. The company operates in two segments, Commercial Banking and Commercial Finance. The Commercial Banking segment provides credit, cash management, and personal banking products and services primarily to small businesses and business owners. It offers a line of mortgage and commercial loans, as well as personal and commercial checking accounts, savings and time deposit accounts, personal and business loans, credit card services, money transfer services, and financial counseling; property, casualty, life, and health insurance agency services; trust services; securities brokerage; and safe deposit facility services. The Commercial Finance segment provides equipment and leasehold improvement financing for franchisees, primarily in the quick service restaurant sector, in the United States. It offers loans to franchisees, including financing of real estate and equipment. The company was founded in 1871 and is headquartered in Columbus, Indiana. Telik, Inc. (NASDAQ: TELK), a clinical stage drug development company, focuses on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The companyas advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the discovery of small molecule drug candidates. The company was founded in 1988 and is based in Palo Alto, California. CombinatoRx, Incorporated (NASDAQ: CRXX), a biopharmaceutical company, focuses on discovering, developing, and outlicensing synergistic combination pharmaceuticals. It develops novel therapeutics with multi-target mechanisms of action that are built from combinations of drugs that utilize novel biology to treat various conditions, including immuno-inflammatory diseases, cancer, metabolic diseases, inherited diseases, and other diseases. The companyas products include Synavive, a novel dissociated glucocorticoid product candidate to enhance the anti-inflammatory benefits of glucocorticoids, which completed phase II in rheumatoid arthritis, knee osteoarthritis, hand osteoarthritis, and biomarker study; CRx-401, an anti-diabetic agent, which is in phase IIa clinical study; and CRx-191, a topical synergistic combination drug candidate that has completed phase IIa clinical trials for psoriasis. Its products also include CRx-197, a novel topical anti-inflammatory product candidate that completed phase IIa clinical trials for the treatment of psoriasis, atopic dermatitis, and other inflammatory dermatoses; and CRx-170, an oral synergistic combination drug candidate, which completed phase IIa clinical trial for the potential treatment of chronic pain conditions. CombinatoRx, Incorporated has collaborations with Angiotech Pharmaceuticals, Inc.; Fovea Pharmaceuticals SA; Cystic Fibrosis Foundation Therapeutics Incorporated; CHDI, Inc.; Charleyas Fund and the Nash Avery Foundation; National Institutes of Allergy and Infectious Diseases; HenKan Pharmaceutical Company; Spinal Muscular Atrophy Foundation; Sirtris Pharmaceuticals, Inc.; and Novartis AG. The company was founded in 2000 and is based in Cambridge, Massachusetts. Arbinet Corporation (NASDAQ: ARBX) provides solutions for the telecommunications industry based upon an electronic market for trading, routing, and settling communications capacity. The company offers voice exchange products and services consisting of PrimeVoice that rematches orders and updates a selleras quality profile; SelectVoice for quality sensitive buyers to trade with the highest quality sellers; DirectAxcess, which gives members a direct connection to fixed and mobile networks; RapidClear, an accelerated settlement service; and SoftSwitchAxcess that allows communications services providers, including non-members to outsource voice over Internet protocol switching and control routing. Its other voice exchange products and services comprise AssuredAxcess, a service that automatically routes a buyeras call directly to its destination; PrivateExchange, an outsourced solution that allows communications services providers to manage their bilateral commercial agreements, including rate negotiations; and Global Number Portability Query Services, which enable a carrier to query its systems for information about the carrier currently serving an end customer in order to route and rate the call correctly. It also offers Internet exchange products and services, including OptimizedIP, SelectIP, and PrimeIP. These products provide Internet protocol transit and peering services to the Internet service providers and content sites. The company was formerly known as Arbinet-thexchange, Inc. and changed its name to Arbinet Corporation in June 2009. Arbinet Corporation was founded in 1996 and is headquartered in New Brunswick, New Jersey. Physicians Formula Holdings, Inc. (NASDAQ: FACE) engages in the development, manufacture, and marketing of cosmetics for the mass market channel. The companyas products comprise face powders, bronzers, concealers, blushes, foundations, eye shadows, eye liners, brow makeup, and mascaras. It sells its products under the masstige brand name to various retailers in the food retail, drug chain, mass volume, specialty retail, and wholesale channels in the United States, Canada, and internationally. The company was founded in 2003 and is headquartered in Azusa, California. ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), a development stage biopharmaceutical company, focuses on the development and commercialization of proprietary small molecule drug candidates that are related to cancer therapeutics. Its primary product includes Palifosfamide (Zymafos or ZIO-201), which is in phase II randomized controlled trial for the treatment of metastatic or unresectable soft tissue sarcoma as front- or second-line therapy. The companyas products in Phase I and/or II studies include Darinaparsin (Zinapar or ZIO-101), a novel anti-mitochondrial agent for the treatment of acute promyelocytic leukemia and for various other cancers; and Indibulin (Zybulin or ZIO-301), a novel small molecular-weight tubulin polymerization inhibitor. It has collaboration agreement with Harmon Hill, LLC to provide consulting and other services related to the companyas development and commercialization of oncology therapeutics. The company was founded in 2003 and is based in New York, New York. SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com One example from the SqueezeTrigger database is approximately 2.6 billion short sale transactions going back to January 1, 2005, and SqueezeTrigger calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com Go to www.SqueezeTrigger.com to find out the exact price that the entire Total Short Interest will start covering! About SQUEEZETRIGGER.COM WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades. SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each monthas short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin. All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind. Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC. SqueezeTrigger is a registered trademark, Reg. No. 3,120,641 CONTACT: Thomas Ronk, CEO, SqueezeTrigger.com Tel: +1 800 715 9999 e-mail: [email protected] WWW: http://www.SqueezeTrigger.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected]. |